Aging and the Heart
The world population of the elderly is approximately 610 million and will grow to approximately 2 billion by 2050. In the year 2000, there were approximately 35 million people in the USA who were 70 years and older. In the year 2030, the number will be approximately 70 million.
Coronary heart disease (CHD) and stroke occur worldwide in all populations and in all races. More than 60% of these individuals have hypertension, which is an important underlying cause of atrial fibrillation, a serious abnormal heart rhythm that is common in the age group 70–90; this condition requires treatment with a blood thinner, warfarin, to prevent strokes.
The main underlying cause for atrial fibrillation is hypertension and aging ( Atrial Fibrillation).
- Beckett NS, Peters R, Fletcher AE et al for the HYVET Study Group (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1898Google Scholar
- Khan M Gabriel (2007) Beta blockers the cornerstone of cardiac drug therapy. In Cardiac Drug Therapy, seventh edition. Humana Press, New Jersey. Page 31 chapter beta blockersGoogle Scholar
- Rossebø AB, Pedersen TR, Boman K et al for the SEAS Investigators (2008) Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359:1343–1356Google Scholar
- Chan KL, Teo K, Dumesnil JG et al for the ASTRONOMER Investigators (2010) Effect of lipid lowering with rosuvastatin on progression of aortic stenosis. Results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) Trial. Circulation 121:306–314. ASTRONOMERGoogle Scholar
- Homocysteine lowering with folic acid and B vitamins in vascular disease (2006) N Engl J Med 354:1567–1577. HOPE-TOO: The Heart Outcomes Prevention Evaluation InvestigatorsGoogle Scholar
- Massie BM, Carson PE, McMurray JJ et al the I-PRESERVE Investigators (2008) Irbesartan in patients with heart failure and preserved ejection fraction. NEJM 359:2456–2467. I-PRESERVEGoogle Scholar
- Pitt B, Remme W, Zannad F et al (2003b) Eplerenone, a selective aldosterone blocker, in patients with left venticular dysfunction after myocardial infarction. New Eng J Med 348:1309–1321. EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study investigatorsPubMedGoogle Scholar
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2000) JAMA 283:1967–1975. ALLHAT: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialGoogle Scholar
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 288:2981–2997. ALLHATGoogle Scholar
- The effect of spironolactone on morbidity and mortality in patients with severe heart failure (1999) N Engl J Med 341:709–717. RALES: The Randomized Aldactone Evaluation Study investigatorsGoogle Scholar
- van Veldhuisen DJ, Cohen-Solal A, Bohm M et al SENIORS Investigators (2009) Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure). J Am Coll Cardiol 53:2150–2158. SENIORSGoogle Scholar